Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.53 |
| ▸ | CA1 | P00915 | 5/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CTSK | P43235 | 3/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.39 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18401365 | 0.94 | CA2 (0.50) | CA2CA1NAMPTCTSKNR1H2 | |
| SCHEMBL18401386 | 0.93 | CA2 (0.49) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL8381013 | 0.91 | CA2 (0.49) | CA2CA1NAMPTCTSKNPC1 | |
| SCHEMBL15684582 | 0.91 | CA2 (0.49) | CA2CA1NAMPTPTGER4NPC1 | |
| SCHEMBL8381191 | 0.89 | ESRRG (0.48) | CA2CA1CTSKSIGMAR1NR1H2 | |
| SCHEMBL24670449 | 0.89 | CA2 (0.48) | CA2CA1NAMPTCTSKNR1H2 | |
| SCHEMBL20852622 | 0.88 | CA2 (0.48) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL29958774 | 0.85 | CA2 (0.47) | CA2CA1NAMPTCTSKNR1H2 | |
| SCHEMBL29958435 | 0.84 | CA2 (0.46) | CA2CA1NAMPTCTSKSIGMAR1 | |
| SCHEMBL16208880 | 0.84 | CA2 (0.50) | CA2CA1NAMPTCTSKSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8703825-B2 | Compounds, use thereof as medicaments, and method of preparation thereof | UNIVERSITE DE LORRAINE (FR) | 2014-04-22 | — | — | US | disclosed |
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | UNIVERSITE HENRI POINCARE NANCY 1 (FR) | 2011-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110184070-A1 | NOVEL COMPOUNDS, USE THEREOF AS MEDICAMENTS, AND METHOD OF PREPARATION THEREOF | CYP11B2, NPM1, B2M | CA2 208/4885CA1 642/4885NAMPT 1149/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.